MyoPax Secures B# Plus Funding From IBB Ventures To Advance Gene-Repair Muscle Stem Cell Therapies
· pulse2.com · popularity 20/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at pulse2.com →
Summary
MyoPax, a biotechnology startup developing gene-repair and regenerative muscle stem cell therapies, has secured funding through IBB Ventures' B# Plus initiative. The post MyoPax Secures B# Plus Funding From IBB Ventures To Advance Gene-Repair Muscle Stem Cell Therapies appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.